WILMINGTON, Mass., April 2, 2018 /PRNewswire/ -- CutisPharma announced today the commercial launch of FIRVANQ™ (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile ...

WILMINGTON, Mass., Jan. 29, 2018 /PRNewswire/ -- CutisPharma announced today that the US Food and Drug Administration (FDA) has approved FIRVANQ™ (vancomycin hydrochloride) for oral solution, for the ...

Vancomycin is indicated to treat enterocolitis caused by Staphylococcus aureus and antibiotic-associated pseudomembranous colitis caused by C. difficile. ANI Pharmaceuticals announced that the Food ...

The FDA on Monday granted approval to CutisPharma's drug Firvanq to treat Clostridium difficile-associated diarrhea and Staphylococcus aureus-associated intestinal inflammation (enterocolitis). Here ...

BAUDETTE, Minn., Sept. 11, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Vancomycin HCl for Oral Solution, 250mg per 5mL (the generic equivalent ...

WILMINGTON — CutisPharma announced that the US Food and Drug Administration has approved FIRVANQ (vancomycin hydrochloride) for oral solution for the treatment of Clostridium difficile associated ...

Azurity Pharmaceuticals, Inc. — a pioneer drug company that markets its FDA-approved oral vancomycin hydrochloride solution, FIRVANQ® — has sued Edge Pharma, LLC, an outsourcing facility operating ...

LEDGEWOOD, N.J.--(BUSINESS WIRE)--ImprimisRx, America’s #1 Ophthalmic Pharmacy™, today announced the availability of Fortisite™, which includes a patent-pending compounded combination of Tobramycin ...

During the manual bottle filling stage of manufacturing, some bottles may have been overfilled resulting in an over potent dosing regimen. Amneal Pharmaceuticals, LLC is voluntarily recalling 4 lots ...

The FDA on Monday granted approval to CutisPharma’s drug Firvanq to treat Clostridium difficile-associated diarrhea and Staphylococcus aureus-associated intestinal inflammation (enterocolitis). Here ...